HARNESSING INTEGRINS
Using integrin science to target disease at its source
Integrins, which are naturally occurring cell surface proteins, are the focus of our two-pronged scientific approach:
1. Integrin inhibition
2. Integrin-mediated delivery
1. Integrin inhibition
Integrins are normally expressed at low levels, but in certain diseases they are upregulated. This upregulation can cause issues such as the continuous activation of TGF-β. Our lead product candidate, PLN-101095, is an integrin inhibitor that targets the TGF-β pathway and is currently being studied in the FORTIFY clinical trial for the treatment of solid tumors.
Developing product candidates that inhibit integrins and
related pathways
With a deep understanding of integrin biology, as well as medicinal chemistry and translational medicine expertise, we have developed a set of proprietary tools to probe the molecular drivers of disease to identify new targets and discover candidates that inhibit dysregulated integrins and related pathways. By utilizing our proprietary library of over 15,000 integrin binding molecules, a comprehensive screening assay system (binding, integrin confirmation, ligand-induced internalization) and an industry-leading live human tissue program, we are creating a deep well of potential drug candidates.
2. SELECTIVE TARGETED INTEGRIN-MEDIATED DELIVERY PLATFORM
In addition to our integrin inhibition program, we are also developing a highly cell selective integrin-mediated delivery platform, initially focused on RNAi in target indications across multiple cell and tissue types. This platform has its foundation in our integrin-related assets and expertise, including our integrin library (15,000+ proprietary small molecules, >1 million annotated data points), our integrin profiling assays, and our integrin-mediated delivery optimization capabilities.
DELIVERY PLATFORM HIGHLIGHTS
- Cell- and tissue-specific payload delivery – Selective for extrahepatic tissues using integrin-targeting small molecules
- Differentiated from established delivery technologies – Efficient delivery through a unique mechanism of cellular internalization
- Targeting previously intractable cell types – Access discrete tissues by leveraging unique cell type-specific integrin expression profiles
Our Publications
Our team has unmatched expertise in integrin biology, and we value sharing our knowledge. We regularly publish and present our research in a variety of forums to advance the discovery of novel targeted therapies.